Illumina (NASDAQ:ILMN) Hits New 12-Month Low - Time to Sell?

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) reached a new 52-week low on Thursday . The stock traded as low as $76.63 and last traded at $77.53, with a volume of 589920 shares. The stock had previously closed at $81.88.

Analyst Ratings Changes

Several analysts recently weighed in on ILMN shares. Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Canaccord Genuity Group lowered their price objective on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research note on Tuesday, March 11th. Guggenheim dropped their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Stephens reissued an "overweight" rating and issued a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. Finally, Robert W. Baird dropped their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $139.85.

Illumina Price Performance

The company has a market cap of $11.14 billion, a price-to-earnings ratio of -9.15, a P/E/G ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company's 50 day moving average price is $93.03 and its 200 day moving average price is $123.78.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Illumina

Several institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc increased its stake in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new stake in Illumina during the 4th quarter worth about $32,000. Fourth Dimension Wealth LLC acquired a new stake in Illumina in the 4th quarter valued at about $40,000. Assetmark Inc. raised its stake in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina during the fourth quarter valued at approximately $45,000. Institutional investors own 89.42% of the company's stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.